Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy

Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Oct 18, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called ursodeoxycholic acid (UDCA) might help the liver recover after a surgery where part of the liver is removed from a donor. The main goal is to see if taking UDCA can improve the liver's growth and function after this type of surgery compared to a group that does not take the medication. Researchers will check liver function through tests and look at specific markers in the blood that indicate how well the liver is regenerating.

To participate in this trial, you must be a living donor who is having a right lobe of your liver removed for transplant purposes at the Institute of Liver and Biliary Sciences in New Delhi. You’ll need to be between certain age limits and meet other health criteria. If you join the study, you will receive either the UDCA supplement or not, and doctors will monitor your recovery closely. This trial is important because it could help improve recovery for liver donors in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All live donors undergoing Right Donor Hepatectomy in ILBS from ethical board clearance to December 2024 in the Department of HPB Surgery and Liver Transplantation, Institute of Liver and Biliary Sciences, New Delhi
• Exclusion Criteria:
• • Negative consent
• • Hypersensitivity to UDCA
• • Past history of UDCA use in the last two weeks